These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8387826)

  • 1. The continuing development of gastric acid pump inhibitors.
    Sachs G; Shin JM; Besancon M; Prinz C
    Aliment Pharmacol Ther; 1993; 7 Suppl 1():4-12, discussion 29-31. PubMed ID: 8387826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of gastric acid inhibition.
    Shamburek RD; Schubert ML
    Baillieres Clin Gastroenterol; 1993 Mar; 7(1):23-54. PubMed ID: 8097411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuing development of acid pump inhibitors: site of action of pantoprazole.
    Shin JM; Besancon M; Prinz C; Simon A; Sachs G
    Aliment Pharmacol Ther; 1994; 8 Suppl 1():11-23. PubMed ID: 7514042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric acid secretion: activation and inhibition.
    Sachs G; Prinz C; Loo D; Bamberg K; Besancon M; Shin JM
    Yale J Biol Med; 1994; 67(3-4):81-95. PubMed ID: 7502535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.
    Shamburek RD; Schubert ML
    Gastroenterol Clin North Am; 1992 Sep; 21(3):527-50. PubMed ID: 1355465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lansoprazole: a proton pump inhibitor.
    Garnett WR
    Ann Pharmacother; 1996 Dec; 30(12):1425-36. PubMed ID: 8968456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological aspects of acid secretion.
    Hirschowitz BI; Keeling D; Lewin M; Okabe S; Parsons M; Sewing K; Wallmark B; Sachs G
    Dig Dis Sci; 1995 Feb; 40(2 Suppl):3S-23S. PubMed ID: 7859583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.
    Wallmark B; Lorentzon P; Larsson H
    Scand J Gastroenterol Suppl; 1985; 108():37-51. PubMed ID: 2988109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gastric H,K ATPase as a drug target: past, present, and future.
    Sachs G; Shin JM; Vagin O; Lambrecht N; Yakubov I; Munson K
    J Clin Gastroenterol; 2007 Jul; 41 Suppl 2(Suppl 2):S226-42. PubMed ID: 17575528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton-pump inhibition for acid-related disease.
    Holt S
    South Med J; 1991 Sep; 84(9):1078-87. PubMed ID: 1653998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological basis of omeprazole therapy.
    Sachs G; Wallmark B
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():7-18. PubMed ID: 2562365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressive action of lansoprazole on gastric acidity and its clinical effect in patients with gastric ulcers: comparison with famotidine.
    Sakaguchi M; Ashida K; Umegaki E; Miyoshi H; Katsu K
    J Clin Gastroenterol; 1995; 20 Suppl 2():S27-31. PubMed ID: 7594334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
    Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
    J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.
    Jana K; Bandyopadhyay T; Ganguly B
    J Phys Chem B; 2016 Dec; 120(51):13031-13038. PubMed ID: 27992223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of proton-pump inhibitors in complicated ulcer disease and upper gastrointestinal tract bleeding.
    Howden CW
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S5-11. PubMed ID: 10597118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked increase in gastric acid secretory capacity after omeprazole treatment.
    Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
    Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.